| | |
PAGE
|
| |||
EXPLANATORY NOTE
|
| | | | S-iii | | |
關於本招股説明書副刊
|
| | | | S-iv | | |
前瞻性陳述
|
| | | | S-1 | | |
SUMMARY | | | | | S-3 | | |
THE OFFERING
|
| | | | S-4 | | |
RISK FACTORS
|
| | | | S-6 | | |
USE OF PROCEEDS
|
| | | | S-8 | | |
DILUTION | | | | | S-9 | | |
PLAN OF DISTRIBUTION
|
| | | | S-11 | | |
重要的美國聯邦所得税考慮因素
|
| | | | S-13 | | |
加拿大聯邦所得税的某些考慮因素
|
| | | | S-18 | | |
LEGAL MATTERS
|
| | | | S-20 | | |
EXPERTS | | | | | S-20 | | |
您可以在哪裏找到更多信息
|
| | | | S-20 | | |
通過引用合併某些信息
|
| | | | S-21 | | |
| | |
PAGE
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
我們的證券概述
|
| | | | 7 | | |
我們的股本説明
|
| | | | 8 | | |
我們的授權書説明
|
| | | | 11 | | |
我們的債務證券説明
|
| | | | 13 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 18 | | |
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
LEGAL MATTERS
|
| | | | 22 | | |
EXPERTS
|
| | | | 22 | | |
您可以在哪裏找到更多信息
|
| | | | 22 | | |
| | |
PAGE
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
我們的證券概述
|
| | | | 7 | | |
我們的股本説明
|
| | | | 8 | | |
我們的授權書説明
|
| | | | 11 | | |
我們的債務證券説明
|
| | | | 12 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 17 | | |
PLAN OF DISTRIBUTION
|
| | | | 18 | | |
LEGAL MATTERS
|
| | | | 21 | | |
EXPERTS
|
| | | | 21 | | |
您可以在哪裏找到更多信息
|
| | | | 21 | | |
| | |
PAGE
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
我們的證券概述
|
| | | | 9 | | |
我們的股本説明
|
| | | | 10 | | |
我們的授權書説明
|
| | | | 12 | | |
我們的債務證券説明
|
| | | | 14 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 19 | | |
PLAN OF DISTRIBUTION
|
| | | | 20 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
您可以在哪裏找到更多信息
|
| | | | 25 | | |
|
假設每股公開發行價
|
| | | | | | | | | $ | 3.09 | | |
|
截至2021年12月31日的每股有形賬面淨值
|
| | | $ | 1.17 | | | | | | | | |
|
每股有形賬面價值的增加歸因於(I)我們2022年1月6日的收據
根據獨家許可,齊魯支付4000萬美元的預付現金 我們於2021年12月與齊魯簽訂協議,(Ii)3579,952份共同協議 2022年1月6日發行的股票,淨收益為1500萬美元 2021年12月與齊魯簽訂購股協議 |
| | | $ | 0.34 | | | | | | | | |
|
截至2021年12月31日的預計每股有形賬面淨值
|
| | | $ | 1.51 | | | | | | | | |
|
本次發行後每股預計有形賬面淨值增加
|
| | | $ | 0.26 | | | | | | | | |
|
預計為截至2021年12月31日的調整後每股有形賬面淨值
此優惠生效 |
| | | | | | | | | $ | 1.77 | | |
|
本次發行向新投資者每股攤薄(1)(2)
|
| | | | | | | | | $ | 1.32 | | |
|
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
我們的證券概述
|
| | | | 7 | | |
我們的股本説明
|
| | | | 8 | | |
我們的授權書説明
|
| | | | 11 | | |
我們的債務證券説明
|
| | | | 13 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 18 | | |
PLAN OF DISTRIBUTION
|
| | | | 19 | | |
LEGAL MATTERS
|
| | | | 22 | | |
EXPERTS
|
| | | | 22 | | |
您可以在哪裏找到更多信息
|
| | | | 22 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
我們的證券概述
|
| | | | 7 | | |
我們的股本説明
|
| | | | 8 | | |
我們的授權書説明
|
| | | | 11 | | |
我們的債務證券説明
|
| | | | 12 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 17 | | |
PLAN OF DISTRIBUTION
|
| | | | 18 | | |
LEGAL MATTERS
|
| | | | 21 | | |
EXPERTS
|
| | | | 21 | | |
您可以在哪裏找到更多信息
|
| | | | 21 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
前瞻性陳述
|
| | | | 2 | | |
THE COMPANY
|
| | | | 4 | | |
RISK FACTORS
|
| | | | 5 | | |
USE OF PROCEEDS
|
| | | | 6 | | |
SELLING SHAREHOLDER
|
| | | | 7 | | |
我們的證券概述
|
| | | | 9 | | |
我們的股本説明
|
| | | | 10 | | |
我們的授權書説明
|
| | | | 12 | | |
我們的債務證券説明
|
| | | | 14 | | |
DESCRIPTION OF OUR UNITS
|
| | | | 19 | | |
PLAN OF DISTRIBUTION
|
| | | | 20 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
您可以在哪裏找到更多信息
|
| | | | 25 | | |
Name and
Address |
| |
Number of Shares
Beneficially Owned Prior to Offering |
| |
Number of
Shares Registered for Sale |
| |
Number of Shares
to be Owned after the Offering |
| |
Percent of Outstanding
Shares to be Owned after the Offering |
| ||||||||||||
Roivant Sciences Ltd.(1)
|
| | | | 38,847,462(1) | | | | | | 38,847,462 | | | | | | —(2) | | | | | | —(2) | | |